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Abstract
Background Melanoma accounts for 90% of skin cancer mortality and typically presents in primary care, where it can
be challenging to distinguish from benign lesions. Dermoscopy is a tool for skin visualization that is routinely used for
melanoma diagnosis in secondary care. However, the role of dermoscopy in primary care remains unclear.
Objectives To determine views on, and use of, dermoscopy by dermatology-interested general practitioners (GPs).
Methods An online questionnaire was emailed to the UK Primary Care Dermatology Society members in February
2018, and responses collected over the following 4 weeks.
Results A total of 205 responses were analysed. Most respondents were GPs (94%), aged over 50 (53%), had a post-
graduate dermatological qualification (67%) and used dermoscopy regularly when reviewing pigmented skin lesions
(97%). Dermoscopy use was commoner amongst GPs who had worked longer in primary care and had experience of
secondary care dermatology. Most had undertaken training in dermoscopy (91%), although one-fifth (20%) had not
updated their training in over 5 years. Most of those who had received only 1 day of face-to-face training reported feel-
ing confident using a dermatoscope. Few respondents (11%) reported access to teledermatology or teledermoscopy for
urgent or routine referrals.
Conclusions UK GPs with a special interest in dermatology are routinely using dermoscopy in the primary care setting.
More research is needed to establish optimal approaches to training and updating GP dermoscopy skills. When
dermoscopy has been shown to be safe, effective, acceptable and cost-effective in this setting, more GPs may also be
able to gain and maintain the skills to implement dermoscopy into routine primary care. Technological advances,
including incorporation of artificial intelligence (AI) and algorithms to guide GPs, could also contribute to widening use of
dermoscopy among GPs.
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Introduction
Cutaneous malignant melanoma (‘melanoma’) accounts for
90% of all skin cancer mortality.1 The incidence has been
increasing rapidly in most developed countries for the past
several decades,2,3 particularly where Caucasian populations are
frequently exposed to sunlight4; in the UK, incidence has
quadrupled since the 1970s.5 If melanoma can be detected and
surgically treated before metastatic spread occurs, prognosis is
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greatly improved.1 The most likely setting for first presentation
and early detection is primary care (>84% in English routinely
collected data6), and general practitioners (GPs), therefore, need
to be able to triage pigmented skin lesions for appropriate
referral and management, or safe follow-up.
Unfortunately, distinguishing between melanoma and
benign pigmented skin lesions clinically is challenging. Diag-
nostic aids for melanoma diagnosis in primary care are
clearly desirable, but tools that improve diagnostic accuracy
in dermatology settings may not be appropriate for primary
care where the prevalence of melanoma is low. A randomized
controlled trial set in English primary care found that the use
of one such tool, the MoleMate system incorporating SIA-
scopy with a primary care algorithm, was as accurate as rou-
tine care but increased the number of referrals.7 Furthermore,
even if diagnostic aids do show efficacy in appropriate trial
settings, they must be cost-effective and acceptable to GPs
and patients if they are to be integrated effectively into rou-
tine practice.
Dermoscopy–also known as dermatoscopy, surface micro-
scopy and epiluminescence microscopy–is a non-invasive diag-
nostic aid for evaluation of skin lesions using a hand-held
magnifying lens and immersion fluid, polarization, or both, to
eliminate surface reflection at the skin–air interface and closely
visualize the skin.8 This allows better visualization of sub-sur-
face structures and colours.9 When used by expert dermatolo-
gists, dermoscopy shows superior sensitivity to naked eye
examination for melanoma detection, without a decrease in
specificity.10–12 In specialist care, its use is, therefore, recom-
mended by UK and other European guidelines,1,13 and data
from Butler et al.14 have showed that regular clinical use of
dermoscopy amongst UK dermatologists increased from 54.0%
in 2003 to 98.5% in 2012. Dermoscopy is not currently recom-
mended for use by GPs in the UK,15 although it is used rou-
tinely by GPs in Australia,16 which has the highest incidence
of melanoma worldwide.
The evidence for dermoscopy use by expert dermatologists
may not translate to primary care where clinicians have less
experience and training in pigmented skin lesion diagnosis
and dermoscopy. In this setting, evidence for the diagnostic
accuracy of dermoscopy is limited. Our group has recently
undertaken a systematic review of the evidence for der-
moscopy use in primary care (paper in submission17), despite
a limited evidence base the results suggest dermoscopy, with
training, improves diagnostic accuracy for melanoma and
benign lesions and reduced unnecessary excisions and referrals.
The extent of training required for a meaningful improvement
in performance is unclear, with some studies showing
improved diagnostic accuracy after only short training inter-
ventions.18–21 It is clear that some training is necessary; even
amongst dermatologists, dermoscopy without training per-
forms no better than naked eye examination.11,22,23
Previous studies have surveyed the frequency of dermato-
scope use and attitudes towards dermoscopy of primary care
practitioners (PCPs) in Australia16 and France,24 finding that
34% and 8%, respectively, use dermoscopy; however, there are
no such data from GPs in the UK. We therefore aimed to per-
form a national survey of UK GP views on dermoscopy and
chose to set this among dermatology-interested GPs, as they




An online questionnaire was emailed via the Primary Care Der-
matology Society to their regular mailing list, comprising
approximately 1600 UK GPs and other PCPs (see Table 1). The
Primary Care Dermatology Society membership consists mainly
of GPs, but is open to any primary care practitioner, is affiliated
to the British Association of Dermatologists and delivers educa-
tional events and online learning. The questionnaire was avail-
able for respondents between 13 February and 13 March 2018.
The survey took approximately five minutes to fully complete,
and responses were voluntary and anonymous. Respondents
could optionally enter a prize draw for online shopping gift
cards, but were not otherwise compensated.
Survey instrument
The questionnaire (reproduced in full in Appendix S1) was
adapted from a previous survey25 assessing attitudes of pri-
mary care physicians towards cancer care and also included
new questions generated specifically for this study and
informed by expert opinion. A previous pilot of this survey
(n = 77) addressing the use of checklists and dermoscopy for
pigmented skin lesion diagnosis in primary care was emailed
to the Royal College of General Practitioner’s weekly mailing
list. This pilot survey was subsequently refined to focus on
dermoscopy use.
In this final version, there were 26 questions in three sections.
The first section (9 questions) focused on demographics, using
questions from the previous surveys regarding age and gender,
new items were added to characterize experience with dermatol-
ogy and skin cancer. The second section (4 questions) focused
on the characteristics of the respondent’s general practice, with
items from the previous surveys regarding practice location, pri-
mary care software and use of checklists for 2-week wait referral
pathways for suspicious pigmented skin lesions. The third sec-
tion (13 questions) focused on use of dermoscopy and teleder-
moscopy; it included questions from the previous surveys
regarding dermoscopy use, use of dermoscopy checklists, confi-
dence with dermoscopy use, extent and modality of previous
dermoscopy training, dermoscopy use within the practice; and
also newly developed questions on the availability of
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teledermatology and teledermoscopy for urgent and routine der-
matology referrals.
Quantitative survey items utilized ‘yes/no’ responses and five-
point Likert scales for the frequency of dermoscopy use
(1 = never to 5 = every time) and the self-reported confidence
in pigmented skin lesion diagnosis and dermoscopy use
(1 = very confident to 5 = very unconfident). Some survey
items allowed free text responses regarding type and duration of
training.
Statistical analysis
Responses were collected via Qualtrics (2018) and exported to
Microsoft Excel (2016). Free text responses were manually parsed
and, where possible, grouped into discrete categories. Geographi-
cal locations of practices were categorized into NHS trust and
health boards according to official NHS structural information
for each of the countries of the UK.26–29 English NHS trusts were
then categorized into North, South, Midlands and East, and Lon-
don mirroring allocation in the NHS digital statistical analysis of
general and personal medical services.30 For the various training
modalities reported, the following categories were used: face-to-
face training, online course training; self-directed study; hands-on
learning; and short didactic training. Statistical analysis was
mainly descriptive. Cross-tab analysis was undertaken to investi-
gate the relationships between certain variables, these included
years worked in primary care vs use of dermoscopy, length of hos-
pital dermatology post vs use of dermoscopy and length of face-
to-face training course vs confidence.
Results
Sample characteristics
A total of 214 responded to the survey, but 9 were less than 50%
complete and were excluded, giving a final sample of 205
respondents. If all 1600 people on the PCDS mailing list received
and read the email, this suggests a response rate of 13%; how-
ever, it is likely that some emails did not reach or were not read
by members, therefore this response rate is likely to be an under-
estimate.
Table 1 shows the characteristics of respondents and their
practices. Most respondents were older and more experienced
than the national average, with 53.1% of our respondents aged
51 and over. In comparison, 33.6% of English GPs are 50 or
older.30 The vast majority of respondents were GPs (93.7%).
Most respondents had previous experience in dermatology;
62.7% had previously held either a hospital dermatology or
GP with extended role (GPwER) post (previously GP with a
special interest, GPwSI) and 67.3% had at least one dermatol-
ogy-related postgraduate qualification. About 88.8% reported
feeling confident in managing patients presenting with pig-
mented skin lesions. Although in this select population of der-
matology-interested GPs, these findings are not necessarily
surprising.
About 53.2% reported using EMIS (a leading UK primary
care system software provider), in line with other reports that
EMIS has 56% of the market share in England for primary care
system software.31 Geographical location of respondents in Eng-
land was broadly representative of the GP population in Eng-
land30 with slight under-representation of NHS London and
NHS Midlands and East areas. National representation, com-
pared to BMA data,32 showed that Scotland and Northern Ire-
land were slightly over-represented in our sample.
Table 1 Characteristics of respondents and their practices
(n = 205 except where otherwise stated)
Respondent
Gender
(n = 204, missing = 1)
Female 113 (55.4%)
Male 91 (44.6%)




Clinical role Current GP 192 (93.7%)
GP trainee 5 (2.4%)




(n = 204, missing = 1)
No 76 (37.3%)
Yes
>6 months 30 (14.7%)
<6 months 27 (13.2%)






MSc (1 year, full time) 3
Postgraduate Diploma
(1 year, part time)
32
Postgraduate Certificate
(4 months, part time)
102
Other (not specified) 6
Confidence managing
pigmented skin lesions





Software system SystmOne 70 (34.1%)
EMIS/EMIS Web 109 (53.2%)
Vision 24 (11.7%)
Other 2 (1.0%)




Northern Ireland 4 (2.0%)
Scotland 21 (10.2%)
Wales 5 (2.4%)
*2 aesthetic doctors, 1 associate specialist, 1 community specialist, 1 clinical
assistant.
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Access to and use of dermoscopy, and confidence in its
use
Table 2 shows reported access to, and use of dermoscopy, and
confidence in its use. Of those with access to a dermatoscope
(>92%), nearly all used it regularly to assess pigmented skin
lesions (96.8%) and the majority felt confident in using it
(82.1%). About 39.3% had a local colleague using dermoscopy;
however, few had referred to them. Five of the six respondents
who had access to a dermatoscope but did not use dermoscopy
regularly had never held a dermatology or GPwER post and had
no postgraduate dermatology qualifications.
Training in dermoscopy use
Table 3 shows training in dermoscopy use. 91.0% of respondents
reported receiving dermoscopy training, the modality and length
of training was variable, and for 20.3% of these it had been over
5 years since their last dermoscopy training. Face-to-face training
courses, such as those run by the Primary Care Dermatology Soci-
ety (PCDS), were by far the most popular training modality
(66.5%). The majority of respondents who had attended face-to-
face training courses had attended for up to a single day (56.5%)
or between a day and a week (40.9%). The most popular modality
for training updates was self-directed learning (33.5%), but 36.0%
reported that they had never updated their training.
We calculated the relationship between training and confi-
dence in using dermoscopy and found that 74.6% of those that
had received only a single day of face-to-face dermoscopy train-
ing was confident in its use.
Use of teledermoscopy and other teledermatology
technologies
Table 4 shows the availability of teledermatology (using clinical
images) or teledermoscopy (using dermoscopic images) tech-
nologies for referral of skin lesions to secondary care. Most
respondents reported that for urgent (2-week wait) referrals,
teledermatology (75.5%) or teledermoscopy (79.6%) referrals
were not possible locally. 71.2% were unable to use telederma-
tology or teledermoscopy technologies to refer skin lesions rou-
tinely, although there were a few respondents who indicated that
these technologies were being piloted or planned soon.
Discussion
Summary
To our knowledge, this is the first survey investigating the preva-
lence of dermoscopy use and training amongst UK GPs. Our find-
ings suggest that access to a dermatoscope and its frequent use is
commonplace amongst dermatology-interested UK GPs, who
have shown that it is possible to undertake dermoscopy training
and successfully incorporate dermoscopy into routine clinical
practice. We are now interested whether, with careful and tailored
approaches to training and implementation, more GPs might be
able to safely implement dermoscopy into routine primary care.
Most respondents were GPs and had a postgraduate dermato-
logical qualification. Nearly all used dermoscopy regularly and
with confidence, as might be expected from this special interest
group, although 7% reported no access to a dermatoscope. Der-
moscopy use was commoner amongst GPs who had worked
longer in primary care and had experience of secondary care der-
matology. Most respondents had undertaken training in der-
moscopy, although one-fifth had not updated their dermoscopy
skills in over 5 years. Clearly, this is an issue for revalidation in
these specialist skills. One respondent indicated that having
completed a dermoscopy training course, they were ‘under so
much pressure at work haven’t had time to sit in [. . .] to learn
how to use dermatoscope in clinic and gain practical experi-
ence’, suggesting pressure from clinical responsibilities prevented
them from continuing their dermoscopy education. Most of
Table 2 Reported access to, and use of dermoscopy, and confidence in its use (n = 205 except where otherwise stated)
Ownership of a dermatoscope Yes 178 (86.8%)
No 27 (13.2%)
Dermatoscope available at work Yes 190 (92.7%)
No 15 (7.3%)
Use of dermoscopy when reviewing pigmented
skin lesions (n = 190)
Yes, Every time 164 (86.3%)
Most of the time 20 (10.5%)
Sometimes 0 (0%)
But rarely 4 (2.1%)
No, never 2 (1.1%)
Confidence in using dermoscopy
(n = 190)




Colleague in practice or locally who uses
dermoscopy
(n = 201, missing = 4)
Yes, And I refer to them 34 (16.9%)
But I have never referred 45 (22.4%)
Not sure 9 (4.5%)
No 113 (56.2%)
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those who had received only one day of face-to-face training felt
confident using a dermatoscope; however, there is an important
distinction between confidence and clinical competence, and
research is needed to establish if this level of training produces a
measurable improvement in diagnostic accuracy.
Few respondents reported access to teledermoscopy or teleder-
matology for either urgent (2-week wait) or routine referrals, sug-
gesting these technologies are not yet widely available. As the
recent NHS Long Term Plan33 identifies the increased integration
of digital technologies as one of the key aims for the NHS, access
to teledermatology is clearly one area that could be targeted.
Strengths and limitations
The current UK policy and clinical drive to encourage GPs to
incorporate dermoscopy into their routine practice, based on
international but not UK evidence for its effectiveness and cost-
effectiveness, makes this study very topical. Our sample was rep-
resentative of the UK GP population in terms of gender and
geography (including practitioners from all four UK nations),
but was older, and enriched by GPs with an interest in dermatol-
ogy. This was due to our recruitment strategy using the PCDS
mailing list. These GPs are the most likely to be early adopters of
routine dermoscopy in primary care, and their views on use,
Table 4 Use of teledermatology and teledermatology-related technologies
Does your 2-week wait referral pathway for
suspicious pigmented skin lesions use tele-
dermatology?
(n = 196, missing = 9)
Yes via digital camera images 17 (8.7%)
via smartphone images 15 (7.7%)
via digital video images 1 (0.5%)
via live video 0 (0%)
No Not at all 138 (70.4%)
Previously available but no longer 6 (3.1%)
Available for other lesions 1 (0.5%)
But service planned to start soon 3 (1.5%)
Not sure 15 (7.7%)
Does your 2-week wait referral pathway for
suspicious pigmented skin lesions use tele-
dermoscopy?
(n = 196, missing = 9)
Yes via digital camera images 13 (6.6%)
via smartphone images 8 (4.1%)
via digital video images 0 (0%)
via live video 0 (0%)
No not at all 153 (78.2%)
Previously available but no longer 1 (0.5%)
Unusable due to technical issues 2 (1.0%)
Not sure 19 (9.7%)
Table 3 Training in dermoscopy use
Training to use dermoscopy
(n = 201, missing = 4)
Yes 183 (91.0%)
No 18 (9.0%)
Time since last dermoscopy training
(n = 172, missing = 11)
<1 year 55 (32.0%)
1–5 years 82 (47.7%)
>5 years 35 (20.3%)
Modality of dermoscopy training
(multiple responses possible)
(n = 182, missing = 1)
Any face-to-face-course 121
PCDS Beginners (1 day) 43
PCDS Advanced (1 day) 16
Other (not specified) 73
Online course training (12 weeks) 27
Hands-on training 21
Short didactic training 17
Self-directed study 45
Updates to dermoscopy training
(multiple responses possible)
(n = 161, missing = 22)
Any face-to-face-course 49
PCDS Advanced (1 day) 31
Other (not specified) 24
Online course training (12 weeks) 0
Short didactic training 23
Hands-on training 11
Self-directed study 54
Not updated skills 58
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access and training needs have relevance for the implementation
of dermoscopy across the wider GP community.
The main limitation of this study is that we are uncertain of
the denominator, and therefore, we were unable to calculate an
accurate response rate or characterise the non-responders. How-
ever, it is likely that GPs with an interest in dermatology and der-
moscopy would have been more likely to respond to the survey
invitation. While we were able to use validated items for the gen-
eral questions, we developed new items for the specific questions
about dermoscopy use, confidence and training. These were
reviewed and revised by the wider study team and agreed to have
good face validity, but further psychometric validation may have
been desirable. Finally, some practices may have internal referral
mechanisms, so that potentially suspicious pigmented skin lesion
are reviewed by GPs with dermoscopy or GPwER expertise, this
may have affected the responses of GPs in these practices and
would not have been fully captured by our survey.
Comparisons with existing literature
We found almost universal routine dermoscopy use when
reviewing pigmented skin lesions (97%). This is likely to be at
least partly due to two-thirds of our respondents reporting a
personal history of dermatology posts and qualifications, in
keeping with Australian evidence that GP subspecialisation in
dermatology leads to increased rates of dermoscopy use.34 This
very high level of dermoscopy use is closer to that of UK derma-
tologists in 2012 (99%),14 than for primary care practitioners
internationally (34% in Australia in 200716 and 8% in France in
201624), or in our pilot survey of UK GPs without a special
interest in dermatology (n = 77, 17%) (unpublished data).
Recent reviews of dermoscopy use for melanoma diagnosis17,35
point to an increase in diagnostic accuracy for benign lesions
and melanoma when dermoscopy is used by trained GPs, and it
can lead to a reduction in unnecessary referrals and excisions.
There is also international evidence that GPs are receptive to
incorporating dermoscopy into their routine practice.24,36–38
Diagnostic accuracy for dermoscopy users appears to depend
on sufficient training.11,21,23 However, there is little evidence to
confirm the optimal training modality and duration. Educa-
tional interventions in previous randomized controlled trials
have ranged from a single hour21 to 10 h plus further textbook
reading or e-learning.39 However, there is no randomized con-
trolled trial evidence comparing the effects of shorter and longer
training periods. Previous studies have found that perceived
training requirements are amongst the most commonly cited
barriers to implementation of dermoscopy.17,24,40 This study
suggests that 1 day of face-to-face training is sufficient to enable
GPs with a special interest in dermatology to feel confident in
dermoscopy use. However, further research is needed to evaluate
whether this level of training produces a significant improve-
ment in diagnostic accuracy, and whether this approach is also
suitable for GPs without a special interest in dermatology.
Australian RCT evidence showed high drop-out rates of GPs
from longer dermoscopy training schedules.41 Finally, we found
that a substantial minority of respondents had not kept their
dermoscopy training up to date; this may be of more concern if
or when dermoscopy becomes more widely implemented across
UK general practice.
Implications for research and/or practice
This survey shows that dermatology-interested GPs in the UK are
routinely using dermoscopy in the primary care setting, suggest-
ing that it may be feasible for dermoscopy to be more widely
implemented in UK primary care. However, further evidence is
needed to show that dermoscopy is safe, effective, acceptable and
cost-effective in this setting. The survey results also highlight that
further research is needed, particularly around the type and length
of dermoscopy training, and refresher courses required, for effec-
tive dermoscopy use. Optimal dermoscopy training methods
which produce a significant improvement in diagnostic accuracy
need to be established, and review is needed on how to best main-
tain competencies, including how frequently training updates are
needed.
Prior to more widespread implementation, providers and poli-
cymakers will also need evidence of cost-effectiveness. Whilst der-
moscopy is relatively inexpensive compared with other diagnostic
aids such as ultrasound or confocal microscopy, it would still rep-
resent a significant cost were it to be recommended for use by
every GP in the UK. Establishing the optimal position of der-
moscopy in the diagnostic pathway will be important in the
cost-effective assessment, for example whether dermoscopy use
in UK primary care should be at an individual level, a practice
level or a primary care hub level. One dermoscopy-trained GP
per practice has been advocated by the Primary Care Derma-
tology Society.42 Finally, technological advances, including
incorporation of artificial intelligence (AI) for pattern recogni-
tion, and algorithms to guide GPs, could also contribute to
enhanced use of dermoscopy among GPs.
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